Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
Localized Prostate Cancer
Advertisement
Latest News
A novel algorithm identifies patients with high-risk non-metastatic PCa who may benefit from second-generation ARPIs.
Dr. Evan Kovac speaks about his pioneering work with extended reality display technology in urologic surgery and education.
The use of MRI-based monitoring can aid in the avoidance of repeat biopsies, and reduce the chances of undergoing surgery.
Dr. Avudaiappan compares radical prostatectomy with dose-escalated radiation with ADT for the treatment of prostate cancer.
Drs. Posadas and Ambinder reflect on the first AUA guideline update for salvage therapy in prostate cancer in over a decade.
Dr. Marc Dall'Era spotlights the results from a phase 2 trial on neoadjuvant niraparib for DDR-deficient localized PCa.
Prostate Cancer Knowledge Hubs
Curated clinical content based on prostate cancer types, therapies, and technologies
Conference Coverage
At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending
Adding niraparib to abiraterone and prednisone prolongs rPFS in patients with mCSPC harboring HRR gene alterations.
Drs. Ong and Roy detail a multinational real-world analysis of the IRONMAN registry on the significance of PSA>0.2.
Dr. Tagawa explains the rationale for EVOLUTION, a phase II analysis of Lu-PSMA-617 with ipilimumab and nivolumab in mCRPC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.